CAR T-Cell therapy trial for lymphoma pulled before it started
NCT ID NCT06313996
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to compare a CAR T-cell therapy called Liso-cel against standard treatments for adults with follicular lymphoma that had come back or stopped responding to previous therapy. The trial was a large Phase 3 study planned at multiple hospitals worldwide, but it was withdrawn before any patients were enrolled. No results or safety data were collected.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- lisocabtagene maraleucel (Liso-cel, also known as BREYANZI)
- What this could lead to
- If successful, this could offer a more effective treatment option for people with follicular lymphoma that has returned or not responded to prior therapy.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no results are available. CAR T-cell therapies can cause serious side effects like cytokine release syndrome and neurological problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Expected to start
-
Mar 2024
An estimate. Start dates often move.
- Expected to finish
-
Oct 2031
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Participants must have measurable disease. * Participants must have previously been treated with certain defined anti-cancer therapies and their disease must have come back or must have not responded to the previous or last treatment. * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Participants that have histologically confirmed Follicular Lymphoma (FL) (Grade 1, 2, or 3a) corresponding to the most recent relapse prior to screening. * Participants that have Relapsed or refractory FL, as assessed by the Investigator. * Participants that have received at least one prior line and no more than three prior lines of systemic therapy including a combination of an anti-CD20 antibody and an alkylating agent. * Participants that received one prior line of systemic therapy are eligible if they present with high risk features. Exclusion Criteria * Participants must not have any history of heart problems. * Participants must not have any bleeding disorders. * Participants must not have any Central Nervous System involvement by Follicular Lymphoma or other brain conditions. * Other protocol-defined Inclusion/Exclusion criteria apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Relapsed or refractory follicular lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.